ZMAT3

Summary

ZMAT3 (zinc finger matrin-type 3, HGNC:29983) is a protein-coding gene on chromosome 3q26.32, encoding Zinc finger matrin-type protein 3 (Q9HA38). Acts as a bona fide target gene of p53/TP53.

This gene encodes a protein containing three zinc finger domains and a nuclear localization signal. The mRNA and the protein of this gene are upregulated by wildtype p53 and overexpression of this gene inhibits tumor cell growth, suggesting that this gene may have a role in the p53-dependent growth regulatory pathway. Alternative splicing of this gene results in two transcript variants encoding two isoforms differing in only one amino acid.

Source: NCBI Gene 64393 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 47 total
• MANE Select transcript: NM_022470

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29983
Approved symbol	ZMAT3
Name	zinc finger matrin-type 3
Location	3q26.32
Locus type	gene with protein product
Status	Approved
Aliases	WIG1, MGC10613, FLJ12296, WIG-1, PAG608
Ensembl gene	ENSG00000172667
Ensembl biotype	protein_coding
OMIM	606452
Entrez	64393

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 10 protein_coding

ENST00000311417, ENST00000414084, ENST00000432729, ENST00000652290, ENST00000867369, ENST00000867370, ENST00000867371, ENST00000867372, ENST00000867373, ENST00000931263

RefSeq mRNA: 8 — MANE Select: NM_022470 NM_001375824, NM_001375825, NM_001375826, NM_001375827, NM_001375828, NM_001375829, NM_022470, NM_152240

CCDS: CCDS3224, CCDS46962

Canonical transcript exons

ENST00000311417 — 6 exons

Exon	Start	End
ENSE00001206616	179027423	179027523
ENSE00001206618	179027646	179027812
ENSE00001206621	179030880	179030999
ENSE00001206631	179017223	179025228
ENSE00001206636	179067483	179067809
ENSE00003843915	179071595	179071809

Expression profiles

Bgee: expression breadth ubiquitous, 277 present calls, max score 96.50.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.2319 / max 225.5099, expressed in 1814 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
45709	19.7864	1795
45708	10.4612	1544
45710	1.1312	753
45711	0.8232	514
45712	0.7065	400
45707	0.2424	124
45713	0.0809	16

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
postcentral gyrus	UBERON:0002581	96.50	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.37	gold quality
parietal lobe	UBERON:0001872	96.05	gold quality
entorhinal cortex	UBERON:0002728	95.12	gold quality
substantia nigra pars compacta	UBERON:0001965	95.10	gold quality
cauda epididymis	UBERON:0004360	95.03	gold quality
medial globus pallidus	UBERON:0002477	94.95	gold quality
superior frontal gyrus	UBERON:0002661	94.42	gold quality
globus pallidus	UBERON:0001875	94.26	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.09	gold quality
middle temporal gyrus	UBERON:0002771	93.85	gold quality
superior vestibular nucleus	UBERON:0007227	93.47	gold quality
germinal epithelium of ovary	UBERON:0001304	92.62	gold quality
ventral tegmental area	UBERON:0002691	92.54	gold quality
lateral nuclear group of thalamus	UBERON:0002736	92.37	gold quality
inferior vagus X ganglion	UBERON:0005363	92.30	gold quality
pons	UBERON:0000988	91.68	gold quality
lateral globus pallidus	UBERON:0002476	91.30	gold quality
occipital lobe	UBERON:0002021	91.01	gold quality
dorsal root ganglion	UBERON:0000044	90.97	gold quality
Brodmann (1909) area 46	UBERON:0006483	90.72	gold quality
visceral pleura	UBERON:0002401	90.66	gold quality
trigeminal ganglion	UBERON:0001675	90.51	gold quality
stromal cell of endometrium	CL:0002255	90.39	gold quality
primary visual cortex	UBERON:0002436	90.27	gold quality
nipple	UBERON:0002030	90.16	gold quality
mammary duct	UBERON:0001765	90.04	gold quality
parietal pleura	UBERON:0002400	89.91	gold quality
caput epididymis	UBERON:0004358	89.83	gold quality
subthalamic nucleus	UBERON:0001906	89.67	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.29
E-GEOD-124858	no	506.90

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53, ZNF91

miRNA regulators (miRDB)

334 targeting ZMAT3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-27A-3P	99.98	72.13	2955

Literature-anchored findings (GeneRIF, showing 17)

• Results demonstrate that human Wig-1 can bind different types of double-stranded RNAs (dsRNAs), including dsRNAs resembling small interfering RNAs and microRNAs, and indicate that dsRNA binding has a role in Wig-1-mediated regulation of cell growth. (PMID:16844115)
• Wig-1-binding proteins, hnRNP A2/B1 and RNA Helicase A, both of which are involved in RNA processing, were identified. (PMID:18519039)
• Data demonstrated a direct interaction between Dicer and Wig-1 and both may play a common role in dsRNA-related gene regulation. (PMID:19127773)
• the p53 target Wig-1 is a previously undescribed AU-rich element-regulating protein that acts as a positive feedback regulator of p53, with implications both for the steady-state levels of p53 and for the p53 stress response (PMID:19805223)
• The cellular distribution of the nuclear matrix protein matrin 3 is altered by novel phosphorylation induced by the alphaherpesvirus US3 kinase family. (PMID:20962082)
• WIG-1 might be a novel modifier in esophageal carcinogenesis, and the WIG-1 MAb should be useful in further study of the mechanism in WIG-1-related physiological reactions. (PMID:21050045)
• WIG-1 might be involved in the zinc-induced cell cycle arrest and apoptosis of human esophageal squamous cell carcinoma cells (PMID:21559779)
• Wig-1 knockdown causes a dramatic inhibition of N-Myc expression and triggers differentiation in neuroblastoma cells carrying amplified N-Myc. (PMID:22513872)
• The data indicated a novel role for Wig1 in RNA-induced silencing complex target accessibility, which is a key step in RNA-mediated gene silencing. Fine tuning of p21 levels by Wig1 was essential for the prevention of cellular senescence. (PMID:23085987)
• PSF and MATR3 are cellular host factors that bind viral RNA and promote Rev activity. (PMID:23158102)
• Results suggest a role of Wig-1 as a survival factor that directs the p53 stress response toward cell cycle arrest rather than apoptosis through the regulation of FAS and 14-3-3sigma mRNA levels. (PMID:24469038)
• expression of the p53 target Wig-1 is associated with HPV status and patient survival in cervical carcinoma (PMID:25379706)
• we propose that Wig1, a key p53 downstream molecule in HD condition, play an important role in stabilizing mutant Htt mRNA and thereby accelerating HD pathology in the mHtt-p53-Wig1 positive feedback manner (PMID:27206983)
• WIG1 governs the miRNA-dependent and the miRNA-independent recruitment of AGO2 to lower the stability of and suppress the translation of ACOT7 mRNA. (PMID:28472401)
• Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. (PMID:33157015)
• The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma. (PMID:33334821)
• eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1. (PMID:34525951)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	zmat3	ENSDARG00000080021
mus_musculus	Zmat3	ENSMUSG00000027663
rattus_norvegicus	Zmat3	ENSRNOG00000063864
drosophila_melanogaster	CG1231	FBGN0035134
drosophila_melanogaster	dbf	FBGN0287630

Paralogs (9): ZNF346 (ENSG00000113761), ZNF385B (ENSG00000144331), ZMAT2 (ENSG00000146007), ZNF385D (ENSG00000151789), ZNF385A (ENSG00000161642), ZMAT4 (ENSG00000165061), ZMAT1 (ENSG00000166432), KRCC1 (ENSG00000172086), ZNF385C (ENSG00000187595)

Protein

Protein identifiers

Zinc finger matrin-type protein 3 — Q9HA38 (reviewed: Q9HA38)

Alternative names: Zinc finger protein WIG-1, p53-activated gene 608 protein

All UniProt accessions (3): Q9HA38, A0A494C120, C9J8H5

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a bona fide target gene of p53/TP53. May play a role in the TP53-dependent growth regulatory pathway. May contribute to TP53-mediated apoptosis by regulation of TP53 expression and translocation to the nucleus and nucleolus.

Subunit / interactions. Interacts with dsRNA.

Subcellular location. Nucleus. Nucleolus.

Tissue specificity. Highly expressed in adult brain, and moderately in adult kidney and testis. Not detected in fetal brain, heart, pancreas, adrenal gland, liver or small intestine.

Induction. By DNA damage in a p53/TP53-dependent manner. Up-regulated following ionizing radiation in primary squamous cell carcinoma of the lung and in various colon cancer cell lines.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9HA38-1	1	yes
Q9HA38-2	2

RefSeq proteins (8): NP_001362753, NP_001362754, NP_001362755, NP_001362756, NP_001362757, NP_001362758, NP_071915, NP_689426 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003604	Matrin/U1-like-C_Znf_C2H2	Domain
IPR013087	Znf_C2H2_type	Domain
IPR022755	Znf_C2H2_jaz	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR052644	ZMAT3	Family

Pfam: PF12171, PF12874

UniProt features (10 total): zinc finger region 3, compositionally biased region 3, region of interest 2, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HA38-F1	69.64	0.27

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 304 (showing top): LEE_NEURAL_CREST_STEM_CELL_DN, TGCGCANK_UNKNOWN, GCANCTGNY_MYOD_Q6, GOLDRATH_IMMUNE_MEMORY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, TGACCTY_ERR1_Q2, AAAYRNCTG_UNKNOWN, chr3q26, CAGCTG_AP4_Q5, TANG_SENESCENCE_TP53_TARGETS_UP, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GROSS_ELK3_TARGETS_UP, GROSS_HYPOXIA_VIA_ELK3_UP, GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_DN

GO Biological Process (3): apoptotic process (GO:0006915), DNA damage response (GO:0006974), protein transport (GO:0015031)

GO Molecular Function (5): RNA binding (GO:0003723), zinc ion binding (GO:0008270), nucleic acid binding (GO:0003676), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleoplasm (GO:0005654), nucleolus (GO:0005730), plasma membrane (GO:0005886), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
nuclear lumen	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cellular response to stress	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
nucleic acid binding	1
transition metal ion binding	1
cation binding	1
cellular anatomical structure	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

698 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZMAT3	TP53	P04637	703
ZMAT3	CDKN1A	P38936	678
ZMAT3	SESN1	Q9Y6P5	545
ZMAT3	CCNG1	P51959	533
ZMAT3	PHLDA3	Q9Y5J5	521
ZMAT3	DHX9	Q08211	504
ZMAT3	HNRNPA2B1	P22626	502
ZMAT3	DDB2	Q92466	485
ZMAT3	RRM2B	Q7LG56	483
ZMAT3	PERP	Q96FX8	482
ZMAT3	MDM2	Q00987	481
ZMAT3	RPS27L	Q71UM5	480
ZMAT3	FDXR	P22570	477
ZMAT3	BBC3	Q96PG8	477
ZMAT3	AEN	Q8WTP8	466

IntAct

33 interactions, top by confidence:

A	B	Type	Score
ZMAT3	AGO2	psi-mi:“MI:0407”(direct interaction)	0.600
ZMAT3	AGO2	psi-mi:“MI:0915”(physical association)	0.600
PRKRA	ZMAT3	psi-mi:“MI:0915”(physical association)	0.560
ZMAT3	STAU1	psi-mi:“MI:0915”(physical association)	0.560
SIAH1	ZMAT3	psi-mi:“MI:0915”(physical association)	0.560
ZMAT3	PRKRA	psi-mi:“MI:0915”(physical association)	0.560
STAU1	ZMAT3	psi-mi:“MI:0915”(physical association)	0.560
ZMAT3	SIAH1	psi-mi:“MI:0915”(physical association)	0.560
TARBP2	ZMAT3	psi-mi:“MI:0915”(physical association)	0.560
ZMAT3	ACTA2	psi-mi:“MI:0914”(association)	0.530
DHX9	ZMAT3	psi-mi:“MI:0915”(physical association)	0.520
HNRNPA2B1	ZMAT3	psi-mi:“MI:0915”(physical association)	0.520
ZMAT3	DHX9	psi-mi:“MI:0915”(physical association)	0.520
ZMAT3	HNRNPA2B1	psi-mi:“MI:0915”(physical association)	0.520
NS	ZMAT3	psi-mi:“MI:0915”(physical association)	0.370
Itsn2	EIF3F	psi-mi:“MI:0914”(association)	0.350
Gtf3c2	PAPD5	psi-mi:“MI:0914”(association)	0.350
SAMHD1	SF1	psi-mi:“MI:0914”(association)	0.350
MMGT1	DERL1	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350

BioGRID (44): ZMAT3 (Two-hybrid), ZMAT3 (Two-hybrid), ZMAT3 (Two-hybrid), ZMAT3 (Reconstituted Complex), CNOT6 (Affinity Capture-Western), ACTA2 (Affinity Capture-MS), DICER1 (Affinity Capture-MS), SF3A1 (Affinity Capture-MS), SUPV3L1 (Affinity Capture-MS), DCAF17 (Affinity Capture-MS), ISCA1 (Affinity Capture-MS), TARBP2 (Affinity Capture-MS), FTO (Affinity Capture-MS), ZMAT3 (Affinity Capture-MS), ZMAT3 (Affinity Capture-MS)

ESM2 similar proteins: A2VE56, A6QPH9, I3LHS8, O08781, O14545, O54836, P0C6S7, Q14CM0, Q3SZY7, Q3U2E2, Q497H0, Q4R3D6, Q4R970, Q58D05, Q5F3F2, Q5FWF5, Q5R7S6, Q5RDJ2, Q5U2M7, Q5VT97, Q66J85, Q68FE8, Q69Z69, Q6DGF4, Q6FIF0, Q6N043, Q6P2K3, Q70EL2, Q7Z6G8, Q8BIZ1, Q8IWR0, Q8K214, Q8K387, Q8N7W2, Q8N9Z9, Q8NA31, Q8ND82, Q8QFX1, Q91YD3, Q96B23

Diamond homologs: A2RV29, B0JZ85, O08781, O54836, Q0IIC4, Q0VD35, Q28EG9, Q5H9K5, Q5R4W8, Q8AVN9, Q8BZ94, Q9H898, Q9HA38, Q9R0B7, Q9UL40, O88532, Q5REX3, Q5U231, Q6GPM1, Q96KR1, Q17QQ9, Q5PPL1, Q5R6I3, Q99JT5, Q9NPI7, A0A096LPI5, A6NJG6, F2Z398, Q09FC8, Q3V0C1, Q68CZ1, Q8IV13, Q8N9N2, Q8TDM0, Q92918, Q96J02, Q96MD7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1154 predictions. Top by Δscore:

Variant	Effect	Δscore
3:179025025:AT:A	donor_gain	1.0000
3:179025025:ATC:A	donor_gain	1.0000
3:179025044:ATT:A	donor_gain	1.0000
3:179025046:T:A	donor_gain	1.0000
3:179025053:CCG:C	donor_gain	1.0000
3:179025226:CTG:C	acceptor_gain	1.0000
3:179027439:TGTA:T	donor_gain	1.0000
3:179027478:ATTC:A	donor_gain	1.0000
3:179027644:A:AC	donor_gain	1.0000
3:179027645:C:CC	donor_gain	1.0000
3:179027699:C:A	donor_gain	1.0000
3:179027820:C:CT	acceptor_gain	1.0000
3:179030874:TCTCA:T	donor_loss	1.0000
3:179030875:CTCA:C	donor_loss	1.0000
3:179030876:TCA:T	donor_loss	1.0000
3:179030877:CACCT:C	donor_loss	1.0000
3:179030878:ACCT:A	donor_loss	1.0000
3:179030879:C:T	donor_loss	1.0000
3:179030998:CC:C	acceptor_gain	1.0000
3:179030999:CC:C	acceptor_gain	1.0000
3:179067628:T:TA	donor_gain	1.0000
3:179070849:A:AC	donor_gain	1.0000
3:179070850:G:C	donor_gain	1.0000
3:179025013:A:C	donor_gain	0.9900
3:179025016:A:AC	donor_gain	0.9900
3:179025017:C:CC	donor_gain	0.9900
3:179025018:TA:T	donor_gain	0.9900
3:179025025:A:AC	donor_gain	0.9900
3:179025037:C:CA	donor_gain	0.9900
3:179025229:C:CC	acceptor_gain	0.9900

AlphaMissense

1882 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:179025105:A:G	F261S	1.000
3:179025134:A:C	C251W	1.000
3:179025135:C:G	C251S	1.000
3:179025135:C:T	C251Y	1.000
3:179025136:A:G	C251R	1.000
3:179025136:A:T	C251S	1.000
3:179025143:G:C	C248W	1.000
3:179025144:C:G	C248S	1.000
3:179025144:C:T	C248Y	1.000
3:179025145:A:G	C248R	1.000
3:179025145:A:T	C248S	1.000
3:179027690:A:C	H171Q	1.000
3:179027690:A:T	H171Q	1.000
3:179027692:G:C	H171D	1.000
3:179027692:G:T	H171N	1.000
3:179027700:C:A	G168V	1.000
3:179027700:C:T	G168E	1.000
3:179027701:C:G	G168R	1.000
3:179027701:C:T	G168R	1.000
3:179027708:G:C	H165Q	1.000
3:179027708:G:T	H165Q	1.000
3:179027710:G:C	H165D	1.000
3:179027710:G:T	H165N	1.000
3:179027718:G:T	A162D	1.000
3:179027735:G:C	F156L	1.000
3:179027735:G:T	F156L	1.000
3:179027736:A:G	F156S	1.000
3:179027737:A:G	F156L	1.000
3:179027743:C:G	A154P	1.000
3:179027747:A:C	C152W	1.000

dbSNP variants (sampled 300 via entrez): RS1000015846 (3:179052141 T>A,C), RS1000028014 (3:179063763 T>C), RS1000043681 (3:179021501 T>C), RS1000081308 (3:179045507 C>A,T), RS1000118051 (3:179057690 A>T), RS1000123260 (3:179070896 G>A), RS1000162797 (3:179057898 C>A,T), RS1000171617 (3:179034177 T>C), RS1000190361 (3:179057915 T>C), RS1000217277 (3:179041125 T>C), RS1000386259 (3:179064304 T>C), RS1000464738 (3:179064107 A>G), RS1000502502 (3:179029117 C>T), RS1000610609 (3:179045722 G>C,T), RS1000619633 (3:179058195 C>T)

Disease associations

OMIM: gene MIM:606452 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST002037_18	Post-traumatic stress disorder (asjusted for relatedness)	2.000000e-06
GCST004602_139	Mean corpuscular volume	6.000000e-09
GCST004603_256	Platelet count	4.000000e-12
GCST004630_129	Mean corpuscular hemoglobin	3.000000e-10
GCST009391_742	Metabolite levels	9.000000e-06
GCST010002_445	Refractive error	2.000000e-09
GCST90002390_299	Mean corpuscular hemoglobin	1.000000e-21
GCST90002392_320	Mean corpuscular volume	1.000000e-20
GCST90002395_397	Mean platelet volume	5.000000e-15
GCST90002397_88	Mean spheric corpuscular volume	3.000000e-15
GCST90002401_135	Platelet distribution width	3.000000e-14

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0004527	mean corpuscular hemoglobin
EFO:0007984	platelet component distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

86 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects cotreatment, increases expression, increases methylation	6
Valproic Acid	decreases expression, decreases methylation, increases expression, affects expression	6
Cisplatin	affects expression, decreases expression, increases expression, affects cotreatment	5
methylmercuric chloride	increases expression, affects cotreatment	4
Doxorubicin	affects expression, increases expression	4
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
nutlin 3	affects cotreatment, increases expression	2
Acetaminophen	increases expression	2
Daunorubicin	increases expression	2
Mitoxantrone	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Aflatoxin B1	affects expression, increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
chloroacetaldehyde	increases expression	1
triphenyl phosphate	affects expression	1
benzo(b)fluoranthene	affects cotreatment, increases expression	1
bisphenol A	increases expression	1
salinomycin	decreases expression	1
cobaltous chloride	increases expression	1
potassium bromate	increases expression	1
zinc chromate	increases abundance, increases expression	1
fludarabine	increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
ochratoxin A	decreases expression	1
benzo(e)pyrene	decreases methylation	1
3,4-dihydroxy-1,2-epoxy-1,2,3,4-tetrahydrobenz(a)anthracene	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2LR	Abcam HeLa ZMAT3 KO	Cancer cell line	Female
CVCL_D8YE	Ubigene HCT 116 ZMAT3 KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer